TVTX logo

Travere Therapeutics, Inc. (TVTX) Selling, general & administrative expenses

annual SGA:

$0.00-$265.54M(-100.00%)
December 31, 2024

Summary

  • As of today (September 16, 2025), TVTX annual SGA is $0.00, with the most recent change of -$265.54 million (-100.00%) on December 31, 2024.
  • During the last 3 years, TVTX annual SGA has fallen by -$149.88 million (-100.00%).
  • TVTX annual SGA is now -100.00% below its all-time high of $265.54 million, reached on December 31, 2023.

Performance

TVTX SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXincome statement metrics

quarterly SGA:

$0.00-$72.84M(-100.00%)
June 30, 2025

Summary

  • As of today (September 16, 2025), TVTX quarterly SGA is $0.00, with the most recent change of -$72.84 million (-100.00%) on June 30, 2025.
  • Over the past year, TVTX quarterly SGA has dropped by -$64.78 million (-100.00%).
  • TVTX quarterly SGA is now -100.00% below its all-time high of $74.04 million, reached on June 30, 2023.

Performance

TVTX quarterly SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXincome statement metrics

TTM SGA:

-$5.82B-$169.06M(-2.99%)
June 30, 2025

Summary

  • As of today (September 16, 2025), TVTX TTM SGA is -$5.82 billion, with the most recent change of -$169.06 million (-2.99%) on June 30, 2025.
  • Over the past year, TVTX TTM SGA has dropped by -$6.08 billion (-2336.51%).
  • TVTX TTM SGA is now -10511833.21% below its all-time high of -$55.40 thousand.

Performance

TVTX TTM SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXincome statement metrics

Selling, general & administrative expenses Formula

SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development

TVTX Selling, general & administrative expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-100.0%-100.0%-2336.5%
3 y3 years-100.0%-100.0%-3373.4%
5 y5 years-100.0%-100.0%-4743.2%

TVTX Selling, general & administrative expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-100.0%at low-100.0%at low-83.7%at low
5 y5-year-100.0%at low-100.0%at low-250.8%at low
alltimeall time-100.0%at low-100.0%at low<-9999.0%at low

TVTX Selling, general & administrative expenses History

DateAnnualQuarterlyTTM
Jun 2025
-
$0.00(-100.0%)
$138.46M(-31.9%)
Mar 2025
-
$72.84M(>+9900.0%)
$203.23M(+4.4%)
Dec 2024
$0.00(-100.0%)
$0.00(-100.0%)
$194.62M(-24.6%)
Sep 2024
-
$65.62M(+1.3%)
$258.21M(-0.8%)
Jun 2024
-
$64.78M(+0.9%)
$260.39M(-3.4%)
Mar 2024
-
$64.22M(+1.0%)
$269.65M(-0.6%)
Dec 2023
$265.54M(+34.4%)
$63.59M(-6.2%)
$271.38M(+2.5%)
Sep 2023
-
$67.80M(-8.4%)
$264.87M(+6.2%)
Jun 2023
-
$74.04M(+12.3%)
$249.49M(+9.2%)
Mar 2023
-
$65.95M(+15.5%)
$228.44M(+9.2%)
Dec 2022
$197.52M(+31.8%)
$57.09M(+8.9%)
$209.27M(+7.7%)
Sep 2022
-
$52.42M(-1.1%)
$194.26M(+9.2%)
Jun 2022
-
$52.98M(+13.2%)
$177.91M(+11.3%)
Mar 2022
-
$46.79M(+11.2%)
$159.89M(+6.7%)
Dec 2021
$149.88M(+10.4%)
$42.08M(+16.7%)
$149.88M(+4.4%)
Sep 2021
-
$36.06M(+3.1%)
$143.55M(+3.0%)
Jun 2021
-
$34.97M(-4.9%)
$139.43M(-0.0%)
Mar 2021
-
$36.78M(+2.9%)
$139.44M(+2.7%)
Dec 2020
$135.80M(+5.3%)
$35.74M(+11.9%)
$135.80M(+6.4%)
Sep 2020
-
$31.95M(-8.6%)
$127.59M(+1.7%)
Jun 2020
-
$34.97M(+5.5%)
$125.42M(-3.1%)
Mar 2020
-
$33.14M(+20.4%)
$129.42M(+0.4%)
Dec 2019
$128.95M(+24.4%)
$27.53M(-7.5%)
$128.95M(+1.2%)
Sep 2019
-
$29.78M(-23.6%)
$127.37M(+3.0%)
Jun 2019
-
$38.97M(+19.3%)
$123.70M(+12.6%)
Mar 2019
-
$32.67M(+25.9%)
$109.83M(+6.0%)
Dec 2018
$103.65M(+2.3%)
$25.95M(-0.6%)
$103.63M(-0.7%)
Sep 2018
-
$26.11M(+4.0%)
$104.33M(+1.2%)
Jun 2018
-
$25.10M(-5.2%)
$103.07M(-3.5%)
Mar 2018
-
$26.47M(-0.7%)
$106.81M(+3.2%)
Dec 2017
$101.33M
$26.65M(+7.2%)
$103.45M(+0.0%)
Sep 2017
-
$24.85M(-13.8%)
$103.43M(+1.0%)
Jun 2017
-
$28.84M(+24.7%)
$102.42M(+5.8%)
DateAnnualQuarterlyTTM
Mar 2017
-
$23.11M(-13.2%)
$96.79M(+4.3%)
Dec 2016
$92.80M(+16.7%)
$26.63M(+11.6%)
$92.80M(+4.4%)
Sep 2016
-
$23.85M(+2.8%)
$88.86M(+1.8%)
Jun 2016
-
$23.20M(+21.3%)
$87.32M(+4.2%)
Mar 2016
-
$19.13M(-15.7%)
$83.81M(+5.4%)
Dec 2015
$79.54M(+33.4%)
$22.68M(+1.7%)
$79.54M(+5.2%)
Sep 2015
-
$22.31M(+13.3%)
$75.58M(+5.2%)
Jun 2015
-
$19.69M(+32.6%)
$71.84M(+13.2%)
Mar 2015
-
$14.86M(-20.6%)
$63.49M(+8.1%)
Dec 2014
$59.64M(+237.2%)
$18.72M(+0.8%)
$58.73M(+27.1%)
Sep 2014
-
$18.58M(+63.8%)
$46.20M(+49.5%)
Jun 2014
-
$11.34M(+12.4%)
$30.90M(+27.9%)
Mar 2014
-
$10.09M(+63.1%)
$24.16M(+58.2%)
Dec 2013
$17.69M(-41.5%)
$6.19M(+88.9%)
$15.28M(-61.2%)
Sep 2013
-
$3.28M(-28.9%)
$39.34M(+9.1%)
Jun 2013
-
$4.61M(+282.3%)
$36.06M(+14.6%)
Mar 2013
-
$1.21M(-96.0%)
$31.45M(+4.0%)
Dec 2012
$30.26M(>+9900.0%)
$30.25M(>+9900.0%)
$30.25M(>+9900.0%)
Nov 2011
-
$0.00(0.0%)
$600.00(-14.3%)
Aug 2011
-
$0.00(0.0%)
$700.00(0.0%)
May 2011
-
$0.00(-100.0%)
$700.00(0.0%)
Feb 2011
$700.00(-53.3%)
$600.00(+500.0%)
$700.00(+40.0%)
Nov 2010
-
$100.00(>+9900.0%)
$500.00(+25.0%)
Aug 2010
-
$0.00(0.0%)
$400.00(-20.0%)
May 2010
-
$0.00(-100.0%)
$500.00(-66.7%)
Feb 2010
$1500.00(+7.1%)
$400.00(>+9900.0%)
$1500.00(+36.4%)
Nov 2009
-
$0.00(-100.0%)
$1100.00(-54.2%)
Aug 2009
-
$100.00(-90.0%)
$2400.00(+4.3%)
May 2009
-
$1000.00(>+9900.0%)
$2300.00(+35.3%)
Feb 2009
$1400.00(-97.3%)
$0.00(-100.0%)
$1700.00(0.0%)
Nov 2008
-
$1300.00(>+9900.0%)
$1700.00(+325.0%)
Aug 2008
-
$0.00(-100.0%)
$400.00(0.0%)
May 2008
-
$400.00
$400.00
Feb 2008
$52.00K
-
-

FAQ

  • What is Travere Therapeutics, Inc. annual SGA?
  • What is the all time high annual SGA for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. annual SGA year-on-year change?
  • What is Travere Therapeutics, Inc. quarterly SGA?
  • What is the all time high quarterly SGA for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. quarterly SGA year-on-year change?
  • What is Travere Therapeutics, Inc. TTM SGA?
  • What is the all time high TTM SGA for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. TTM SGA year-on-year change?

What is Travere Therapeutics, Inc. annual SGA?

The current annual SGA of TVTX is $0.00

What is the all time high annual SGA for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high annual SGA is $265.54M

What is Travere Therapeutics, Inc. annual SGA year-on-year change?

Over the past year, TVTX annual SGA has changed by -$265.54M (-100.00%)

What is Travere Therapeutics, Inc. quarterly SGA?

The current quarterly SGA of TVTX is $0.00

What is the all time high quarterly SGA for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high quarterly SGA is $74.04M

What is Travere Therapeutics, Inc. quarterly SGA year-on-year change?

Over the past year, TVTX quarterly SGA has changed by -$64.78M (-100.00%)

What is Travere Therapeutics, Inc. TTM SGA?

The current TTM SGA of TVTX is -$5.82B

What is the all time high TTM SGA for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high TTM SGA is -$55.40K

What is Travere Therapeutics, Inc. TTM SGA year-on-year change?

Over the past year, TVTX TTM SGA has changed by -$6.08B (-2336.51%)
On this page